| Li, Xingya |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 99 | US, RoW | Sutetinib Maleate Capsule, Sutetinib | Teligene US | Non-small Cell Lung Cancer | 08/24 | 02/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 140 | RoW | D1553, IN10018（Ifebemtinib）, BI 853520 | InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd | Solid Tumor | 12/25 | 12/26 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06794957: A Study of AL8326 in Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 158 | RoW | AL8326 tablets, AL8326 | Advenchen Laboratories, LLC | Non-small Cell Lung Cancer | 12/27 | 12/27 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT05183243: GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results |
|
|
| Recruiting | 1 | 68 | RoW | GH21 Capsule | Suzhou Genhouse Bio Co., Ltd. | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Neoplasm | 12/24 | 02/25 | | |
NCT05306132: Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 |
|
|
| Recruiting | 1 | 150 | RoW | ASKC202 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 05/24 | 05/25 | | |
NCT05789602: A Study of BPI-460372 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 82 | RoW | BPI-460372 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05729399: Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | GT201 | Grit Biotechnology | Solid Tumor | 05/25 | 05/25 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Zhang, Zhixiang |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
